Statistics and trial design

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Statistics and trial design.php on line 2
Statistics and trial design

LE WE PMID CA

Statistics and trial design

Statistik und Studiendesign

Bayesian statistics

Bioinformatics

Biomarker (BASKET)

Case study approach

Data mining

Drug development

Epidemiology

Evidence based medicine

Genomic and genetic analysis

Glucocorticoids

Informed consent

Intention to treat

Kidney (BASKET)

Microarray (Gene expression analysis)

Neoplasia (Study endpoint)

Neoplasia (Tumor biology and immunology)

Network meta analysis

Nicotine

Number needed to treat

Pediatrics

Personalized medicine

Plazebo

Publication issues

Research ethics

Sepsis

Statistics and trial design

Systematic review

Systemic lupus erythematosus

2006 1	A primer on the use of modern missing-data methods in psychosomatic medicine research. [16738075] Psychosom Med 68(3): 427-36 (2006)
1997 2	Multilevel statistical models for psychosomatic research. [9251152] Psychosom Med 59(4): 350-1 (1997)
1991 3	Meta-analysis: a review. [1882008] Psychosom Med 53(3): 247-71 (1991)
2010 4	The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. [20156912] BMJ 340(-): c365 (2010)
2009 5	Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. [19666685] BMJ 339(-): b2981 (2009)
2006 6	Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. [17060338] BMJ 333(7581): 1248 (2006)
2006 7	Cochrane reviews v industry supported meta-analyses: we should read all reviews with caution. [17068041] BMJ 333(7574): 916 (2006)
2006 8	Cochrane reviews v industry supported meta-analyses: has Cochrane really achieved its goals? [17068040] BMJ 333(7574): 916 (2006)
2006 9	Cochrane reviews v industry supported meta-analyses: ten questions to assess bias in medical research. [17068039] BMJ 333(7574): 916-7 (2006)
2006 10	Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. [17028106] BMJ 333(7572): 782 (2006)
2006 11	The simplest statistical test: how to check for a difference between treatments. [16735336] BMJ 332(7552): 1256-8 (2006)
2005 12	Why clinicians are natural bayesians. [15879401] BMJ 330(7499): 1080-3 (2005)
2005 13	Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. [15860831] BMJ 330(7498): 1021-3 (2005)
2005 14	Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. [15845982] BMJ 330(7497): 960-2 (2005)
2005 15	Reader's guide to critical appraisal of cohort studies: 1. Role and design. [15831878] BMJ 330(7496): 895-7 (2005)
2005 16	Optimal search strategies for retrieving systematic reviews from Medline: analytical survey. [15619601] BMJ 330(7482): 68 (2005)
2004 17	Diagnostic tests 4: likelihood ratios. [15258077] BMJ 329(7458): 168-9 (2004)
2004 18	The logrank test. [15117797] BMJ 328(7447): 1073 (2004)
2002 19	Power is indeed irrelevant in interpreting completed studies. [12458264] BMJ 325(7375): 1304 (2002)
2002 20	Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. [12242181] BMJ 325(7365): 652-4 (2002)
2001 21	Statistics notes: Analysing controlled trials with baseline and follow up measurements. [11701584] BMJ 323(7321): 1123-4 (2001)
2001 22	Sifting the evidence-what's wrong with significance tests? [11159626] BMJ 322(7280): 226-31 (2001)
2000 23	The risk of bias from omitted research. [11021845] BMJ 321(7265): 845-6 (2000)
2000 24	Statistics notes. The odds ratio. [10827061] BMJ 320(7247): 1468 (2000)
2000 25	Scientific, ethical, and logistical considerations in introducing a new operation: a retrospective cohort study from paediatric cardiac surgery. [10784538] BMJ 320(7243): 1168-73 (2000)
1999 26	How to randomise. [10480833] BMJ 319(7211): 703-4 (1999)
1999 27	What is meant by intention to treat analysis? Survey of published randomised controlled trials. [10480822] BMJ 319(7211): 670-4 (1999)
1999 28	A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s. [10463905] BMJ 319(7209): 572-3 (1999)
1999 29	Understanding controlled trials. Randomisation methods: concealment. [10435967] BMJ 319(7206): 375-6 (1999)
1999 30	Statistics notes: variables and parameters. [10373171] BMJ 318(7199): 1667 (1999)
1999 31	Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. [10356018] BMJ 318(7197): 1548-51 (1999)
1999 32	Statistics notes. Treatment allocation in controlled trials: why randomise? [10221955] BMJ 318(7192): 1209 (1999)
1998 33	Survival probabilities (the Kaplan-Meier method). [9836663] BMJ 317(7172): 1572 (1998)
1998 34	Confidence intervals for the number needed to treat. [9804726] BMJ 317(7168): 1309-12 (1998)
1998 35	Bayesians and frequentists. [9784463] BMJ 317(7166): 1151-60 (1998)
1998 36	When placebo controlled trials are essential and equivalence trials are inadequate. [9748192] BMJ 317(7162): 875-80 (1998)
1998 37	The intracluster correlation coefficient in cluster randomisation. [9572764] BMJ 316(7142): 1455 (1998)
1998 38	What's wrong with Bonferroni adjustments. [9553006] BMJ 316(7139): 1236-8 (1998)
1998 39	When can odds ratios mislead? [9550961] BMJ 316(7136): 989-91 (1998)
1998 40	Understanding controlled trials. What is a patient preference trial? [9487173] BMJ 316(7128): 360 (1998)
1998 41	Meta-analysis. Unresolved issues and future developments. [9468698] BMJ 316(7126): 221-5 (1998)
1998 42	Understanding controlled trials. Why are randomised controlled trials important? [9468688] BMJ 316(7126): 201 (1998)
1998 43	Spurious precision? Meta-analysis of observational studies. [9462324] BMJ 316(7125): 140-4 (1998)
1998 44	Statistics notes. Weighted comparison of means. [9462320] BMJ 316(7125): 129 (1998)
1997 45	Meta-analysis. Beyond the grand mean? [9437284] BMJ 315(7122): 1610-4 (1997)
1997 46	Papers that summarise other papers (systematic reviews and meta-analyses). [9310574] BMJ 315(7109): 672-5 (1997)
1997 47	Statistics notes. Trials randomised in clusters. [9302962] BMJ 315(7108): 600 (1997)
1997 48	How to read a paper. Statistics for the non-statistician. II: "Significant" relations and their pitfalls. [9277611] BMJ 315(7105): 422-5 (1997)
1997 49	How to read a paper. Statistics for the non-statistician. I: Different types of data need different statistical tests. [9270463] BMJ 315(7104): 364-6 (1997)
1997 50	Major journals should peer review trials at protocol stage. [9193306] BMJ 314(7095): 1691-2 (1997)
1997 51	Statistics notes. Units of analysis. [9224131] BMJ 314(7098): 1874 (1997)
1996 52	Statistics notes. Logarithms. [8597743] BMJ 312(7032): 700 (1996)
1995 53	Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. [7580713] BMJ 311(7013): 1145-8 (1995)
1994 54	Identifying relevant studies for systematic reviews. [7718048] BMJ 309(6964): 1286-91 (1994)
1994 55	Meta-analysis and its problems. [7950571] BMJ 309(6957): 789-92 (1994)
1994 56	Some examples of regression towards the mean. [7950567] BMJ 309(6957): 780 (1994)
1994 57	Systematic reviews. Some examples. [7950526] BMJ 309(6956): 719-21 (1994)
1994 58	Checklists for review articles. [8086990] BMJ 309(6955): 648-51 (1994)
1994 59	Rationale for systematic reviews. [8086953] BMJ 309(6954): 597-9 (1994)
1985 60	Death of a volunteer. [3158369] Br Med J (Clin Res Ed) 290(6479): 1369-70 (1985)
1983 61	Statistical guidelines for contributors to medical journals. [6405856] Br Med J (Clin Res Ed) 286(6376): 1489-93 (1983)
1979 62	The case-control study. [519216] Br Med J 2(6195): 884-5 (1979)
1992 63	Why clinical trials fail: the hidden assumptions of clinical trials. [1738874] South Med J 85(2): 117-8 (1992)
2002 64	The nature of truth: Simpson's Paradox and the limits of statistical data. [11937652] QJM 95(4): 247-9 (2002)
2000 65	Confidence limits and the limits of confidence. [10700483] QJM 93(2): 121-4 (2000)
1999 66	Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. [10326078] QJM 92(3): 177-82 (1999)
1998 67	The significance of non-significance. [10024920] QJM 91(9): 647-53 (1998)
1998 68	Likelihood ratios: getting diagnostic testing into perspective. [9666947] QJM 91(4): 247-58 (1998)
2009 69	Issues on the selection of non-inferiority margin in clinical trials. [19302756] Chin Med J (Engl) 122(4): 466-70 (2009)
2008 70	Imputation methods for missing outcome data in meta-analysis of clinical trials. [18559412] Clin Trials 5(3): 225-39 (2008)
2005 71	On criteria for evaluating models of absolute risk. [15772102] Biostatistics 6(2): 227-39 (2005)
2001 72	Rethinking historical controls. [12933631] Biostatistics 2(4): 383-96 (2001)
2004 73	Twenty statistical errors even you can find in biomedical research articles. [15311405] Croat Med J 45(4): 361-70 (2004)
2009 74	Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison. [19772573] Trials 10(-): 86 (2009)
2009 75	Design, analysis, and presentation of crossover trials. [19405975] Trials 10(-): 27 (2009)
2008 76	A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. [18694492] Trials 9(-): 51 (2008)
2009 77	Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. [19536325] PLoS Med 6(5): e1000067 (2009)
2009 78	Preventing bias in cluster randomised trials. [19536323] PLoS Med 6(5): e1000065 (2009)
2008 79	In the era of systematic reviews, does the size of an individual trial still matter. [18177203] PLoS Med 5(1): e4 (2008)
2009 80	A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. [20003383] BMC Pediatr 9(-): 77 (2009)
2006 81	Conducting research in individual patients: lessons learnt from two series of N-of-1 trials. [16984636] BMC Fam Pract 7(-): 54 (2006)
2008 82	Teaching statistics in biology: using inquiry-based learning to strengthen understanding of statistical analysis in biology laboratory courses. [18765754] CBE Life Sci Educ 7(3): 317-26 (2008)
2009 83	Application of multivariate probabilistic (Bayesian) networks to substance use disorder risk stratification and cost estimation. [20169014] Perspect Health Inf Manag 6(-): 1b (2009)
2009 84	The use of older studies in meta-analyses of medical interventions: a survey. [19946395] Open Med 3(2): e62-8 (2009)
2008 85	Meta-analysis of multi-arm trials using empirical logistic transform. [19606233] Open Med Inform J 2(-): 112-6 (2008)
2009 86	Meta-analysis: A brief introduction. [20443922] Clin Transl Sci 2(5): 374-8 (2009)
2009 87	Bayesian classification of clinical practice guidelines. [19667308] Arch Intern Med 169(15): 1431-5 (2009)
2004 88	Statistical issues in interpreting clinical trials. [15078496] J Intern Med 255(5): 529-37 (2004)
2004 89	On the evolution of statistical methods as applied to clinical trials. [15078495] J Intern Med 255(5): 521-8 (2004)
1997 90	Interpretation of data from multiple trials: a critical review. [9104430] J Intern Med 241(3): 177-83 (1997)
2007 91	Power: not only a matter of numbers, but also of design. [17587644] Neth J Med 65(6): 197-8 (2007)
2008 92	Meta-analysis: Its strengths and limitations. [18595551] Cleve Clin J Med 75(6): 431-9 (2008)
2008 93	Meta-analyses, metaphysics, and reality. [18595547] Cleve Clin J Med 75(6): 400 (2008)
1999 94	Misuse of correlation and regression in three medical journals. [10396255] J R Soc Med 92(3): 123-8 (1999)
1996 95	Systematic reviews. [8949528] J R Soc Med 89(9): 538 (1996)
1995 96	Pitfalls in the interpretation of studies: III. [7636813] J R Soc Med 88(5): 241-3 (1995)
1995 97	Pitfalls in the interpretation of studies: I. [7884763] J R Soc Med 88(1): 2-4 (1995)
2009 98	Standing on the shoulders of giants: Introduction to systematic reviews and meta-analyses. [19910604] Can Fam Physician 55(11): 1155-6 (2009)
2001 99	Hypothesis: the research page. Part 3: Power, sample size, and clinical significance. [11494932] Can Fam Physician 47(-): 1441-3, 1450-3 (2001)
2008 100	Tips and tricks in performing a systematic review--chapter 4. [18307870] Br J Gen Pract 58(547): 136 (2008)
2007 101	Tips and tricks in performing a systematic review. [18252086] Br J Gen Pract 57(545): 999 (2007)
2007 102	Tips and tricks in performing a systematic review. [17504612] Br J Gen Pract 57(538): 425 (2007)
1996 103	Is there evidence that megatrials are based on a methodological mistake? [8978123] Br J Gen Pract 46(412): 688 (1996)
1996 104	Megatrials are based on a methodological mistake. [8776917] Br J Gen Pract 46(408): 429-31 (1996)
2004 105	On the nature and analysis of clustered data. [15209193] Ann Fam Med 2(3): 199-200 (2004)
1979 106	The four basic types of evaluation: clinical reviews, clinical trials, program reviews, and program trials. [109896] Public Health Rep 94(3): 210-5 (1979)
1997 107	Statistics in the journal--significance, confidence, and all that. [9254553] Am J Public Health 87(7): 1092-5 (1997)
1991 108	The importance of assessing the fit of logistic regression models: a case study. [1746660] Am J Public Health 81(12): 1630-5 (1991)
1984 109	Consensus methods: characteristics and guidelines for use. [6380323] Am J Public Health 74(9): 979-83 (1984)
2009 110	Interpreting results in 2 x 2 tables: part 9 of a series on evaluation of scientific publications. [20038982] Dtsch Arztebl Int 106(48): 795-800 (2009)
2009 111	Placebo: misunderstandings and prejudices. [20019863] Dtsch Arztebl Int 106(46): 751-5 (2009)
2009 112	Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. [19946431] Dtsch Arztebl Int 106(41): 664-8 (2009)
2009 113	Descriptive statistics: the specification of statistical measures and their presentation in tables and graphs. Part 7 of a series on evaluation of scientific publications. [19890414] Dtsch Arztebl Int 106(36): 578-83 (2009)
2009 114	Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications. [19652768] Dtsch Arztebl Int 106(27): 456-63 (2009)
2009 115	Requirements and assessment of laboratory tests: Part 5 of a series on evaluation of scientific publications. [19623307] Dtsch Arztebl Int 106(24): 403-6 (2009)
2009 116	Study design in medical research: part 2 of a series on the evaluation of scientific publications. [19568374] Dtsch Arztebl Int 106(11): 184-9 (2009)
2009 117	Critical appraisal of scientific articles: part 1 of a series on evaluation of scientific publications. [19562021] Dtsch Arztebl Int 106(7): 100-5 (2009)
2008 118	Independent predictors from stepwise logistic regression may be nothing more than publishable P values. [19020117] Anesth Analg 107(6): 1775-8 (2008)
2005 119	The legend of the P value. [16244009] Anesth Analg 101(5): 1454-6 (2005)
2006 120	Better methods for meta-analysis available. [16732124] Anesthesiology 104(6): 1350 (2006)
2000 121	Current issues in clinical trial design: superiority versus equivalency studies. [10839934] Anesthesiology 92(6): 1814-20 (2000)
2000 122	Randomized and nonrandomized clinical studies: statistical considerations. [10754608] Anesthesiology 92(4): 928-30 (2000)
1993 123	Pitfalls in performing meta-analysis: I. [8342859] Anesthesiology 79(2): 405 (1993)
1993 124	Pitfalls in performing meta-analysis: II. [8380047] Anesthesiology 79(2): 406-8 (1993)
2008 125	Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis--funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy. [18671838] Crit Care 12(4): 220 (2008)
2005 126	A systematic evaluation of the quality of meta-analyses in the critical care literature. [16277721] Crit Care 9(5): R575-82 (2005)
2004 127	Statistics review 13: receiver operating characteristic curves. [15566624] Crit Care 8(6): 508-12 (2004)
2005 128	Statistics review 14: Logistic regression. [15693993] Crit Care 9(1): 112-8 (2005)
2005 129	Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments. [15693981] Crit Care 9(1): 34-6; discussion 34-6 (2005)
2004 130	Statistics review 10: further nonparametric methods. [15153238] Crit Care 8(3): 196-9 (2004)
2004 131	Statistics review 9: one-way analysis of variance. [15025774] Crit Care 8(2): 130-6 (2004)
2004 132	Statistics review 12: survival analysis. [15469602] Crit Care 8(5): 389-94 (2004)
2004 133	Statistics review 11: assessing risk. [15312212] Crit Care 8(4): 287-91 (2004)
2004 134	Statistics review 8: Qualitative data - tests of association. [14975045] Crit Care 8(1): 46-53 (2004)
2003 135	Statistics review 7: Correlation and regression. [14624685] Crit Care 7(6): 451-9 (2003)
2002 136	Statistics review 5: Comparison of means. [12398782] Crit Care 6(5): 424-8 (2002)
2002 137	Statistics review 4: sample size calculations. [12225610] Crit Care 6(4): 335-41 (2002)
2002 138	Statistics review 3: hypothesis testing and P values. [12133182] Crit Care 6(3): 222-5 (2002)
2002 139	Statistics review 6: Nonparametric methods. [12493072] Crit Care 6(6): 509-13 (2002)
2002 140	Statistics review 2: samples and populations. [11983040] Crit Care 6(2): 143-8 (2002)
2002 141	Statistics review 1: presenting and summarising data. [11940268] Crit Care 6(1): 66-71 (2002)
2005 142	Advanced statistics: how to determine whether your intervention is different, at least as effective as, or equivalent: a basic introduction. [15930406] Acad Emerg Med 12(6): 536-42 (2005)
2004 143	Advanced statistics: understanding medical record review (MRR) studies. [14759964] Acad Emerg Med 11(2): 187-92 (2004)
2003 144	Bayesian modeling and real-world problems. [12837653] Acad Emerg Med 10(7): 780-2 (2003)
2001 145	Are clinician-investigators Bayesian? [11733298] Acad Emerg Med 8(12): 1179-81 (2001)
2000 146	Research fundamentals: statistical considerations in research design: a simple person's approach. [10691082] Acad Emerg Med 7(2): 194-9 (2000)
1999 147	Systematic reviews: a logical methodological extension of evidence-based medicine. [10609928] Acad Emerg Med 6(12): 1255-60 (1999)
1998 148	Parametric statistical tests: unnecessary assumptions, computers, and the search for the trustworthy p-value. [9835464] Acad Emerg Med 5(11): 1048-50 (1998)
1997 149	Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital "Utstein style". A statement for health care professionals from the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Australian Resuscitation Council, and the Resuscitation Councils of Southern Africa. [9189194] Acad Emerg Med 4(6): 603-27 (1997)
2003 150	Statistical consideration for research. [12748144] Emerg Med J 20(3): 258-62 (2003)
2003 151	Designing a research project: randomised controlled trials and their principles. [12642531] Emerg Med J 20(2): 164-8 (2003)
2003 152	Observational research methods. Research design II: cohort, cross sectional, and case-control studies. [12533370] Emerg Med J 20(1): 54-60 (2003)
2002 153	Overview of research designs. [12421782] Emerg Med J 19(6): 546-9 (2002)
2001 154	Article 8. An introduction to hypothesis testing. Non-parametric comparison of two groups-1. [11435368] Emerg Med J 18(4): 276-82 (2001)
2007 155	Statistics in review. Part 2: generalised linear models, time-to-event and time-series analysis, evidence synthesis and clinical trials. [17536991] Crit Care Resusc 9(2): 187-97 (2007)
2007 156	Statistics in review Part I: graphics, data summary and linear models. [17352672] Crit Care Resusc 9(1): 81-90 (2007)
2004 157	Critical care trials: sample size, power and interpretation. [16556098] Crit Care Resusc 6(4): 239-42 (2004)
2001 158	Reporting of clinical trials using group sequential methods. [16573493] Crit Care Resusc 3(3): 146-7 (2001)
2000 159	Relative risks: relative benefits. [16597309] Crit Care Resusc 2(4): 244-5 (2000)
2000 160	The value of the number-needed-to-treat method in antiepileptic drug trials. [10756410] Epilepsia 41(4): 440-6 (2000)
2004 161	Methods for analysis of skewed data distributions in psychiatric clinical studies: working with many zero values. [15229044] Am J Psychiatry 161(7): 1159-68 (2004)
2004 162	Pitfalls of meta-analyses. [15169713] Am J Psychiatry 161(6): 1131 (2004)
2010 163	Statistics in experimental cerebrovascular research: comparison of more than two groups with a continuous outcome variable. [20571520] J Cereb Blood Flow Metab 30(9): 1558-63 (2010)
2005 164	From the descriptive towards inferential statistics: hundred years since conception of the Student's t-distribution. [15990717] Neuro Endocrinol Lett 26(3): 167-71 (2005)
2007 165	Simulation performance checklist generation using the Delphi technique. [18056208] Can J Anaesth 54(12): 992-7 (2007)
1997 166	Systematic reviews: the case for rigorous methods and rigorous reporting. [9104514] Can J Anaesth 44(4): 350-3 (1997)
2007 167	Consent bias in research: how to avoid it. [17699171] Heart 93(9): 1024-5 (2007)
2006 168	The value of risk scores. [16757542] Heart 92(12): 1713-4 (2006)
2000 169	Evaluation of large scale clinical trials and their application to usual practice. [11083755] Heart 84(6): 679-84 (2000)
1988 170	The end of the p value? [3052552] Br Heart J 60(3): 177-80 (1988)
1989 171	Understanding investigative clinical trials. [2651729] J Vasc Surg 9(4): 609-18 (1989)
2006 172	Methodological issues in cardiovascular epidemiology: the risk of determining absolute risk through statistical models. [17326336] Vasc Health Risk Manag 2(3): 309-15 (2006)
2007 173	Statistics in pharmacology. [17618311] Br J Pharmacol 152(3): 291-3 (2007)
2007 174	Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. [17488364] Br J Clin Pharmacol 63(5): 595-613 (2007)
2004 175	What is a clinical trial? [15206985] Br J Clin Pharmacol 58(1): 1-3 (2004)
2004 176	The revision of the Declaration of Helsinki: past, present and future. [15151515] Br J Clin Pharmacol 57(6): 695-713 (2004)
2002 177	Is intent-to-treat analysis always (ever) enough? [12207643] Br J Clin Pharmacol 54(2): 203-11 (2002)
2001 178	Points to consider on switching between superiority and non-inferiority. [11560553] Br J Clin Pharmacol 52(3): 223-8 (2001)
2001 179	Switching between superiority and non-inferiority: an introductory note. [11560552] Br J Clin Pharmacol 52(3): 221 (2001)
2001 180	Switching between superiority and non-inferiority. [11560551] Br J Clin Pharmacol 52(3): 219 (2001)
2001 181	Stopping rules for phase II studies. [11422011] Br J Clin Pharmacol 51(6): 523-9 (2001)
1979 182	Validity of cross-over trials. [552297] Br J Clin Pharmacol 8(1): 5-6 (1979)
1977 183	Significant or important? [901732] Br J Clin Pharmacol 4(4): 411-2 (1977)
2006 184	Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. [16968952] Pharmacol Rev 58(3): 621-81 (2006)
2005 185	Regression methods in the empiric analysis of health care data. [15804208] J Manag Care Pharm 11(3): 240-51 (2005)
2005 186	Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. [16278497] Can J Clin Pharmacol 12(3): e254-63 (2005)
2005 187	Modeling nonlinear dose-response relationships in epidemiologic studies: statistical approaches and practical challenges. [18648629] Dose Response 3(4): 474-90 (2005)
2005 188	The causes and effects of socio-demographic exclusions from clinical trials. [16181564] Health Technol Assess 9(38): iii-iv, ix-x, 1-152 (2005)
2005 189	Lay public's understanding of equipoise and randomisation in randomised controlled trials. [15763039] Health Technol Assess 9(8): 1-192, iii-iv (2005)
2005 190	Issues in data monitoring and interim analysis of trials. [15763038] Health Technol Assess 9(7): 1-238, iii-iv (2005)
2004 191	Identification and assessment of ongoing trials in health technology assessment reviews. [15525479] Health Technol Assess 8(44): iii, 1-87 (2004)
2003 192	Evaluating non-randomised intervention studies. [14499048] Health Technol Assess 7(27): iii-x, 1-173 (2003)
2001 193	Statistical assessment of the learning curves of health technologies. [11319991] Health Technol Assess 5(12): 1-79 (2001)
2000 194	Bayesian methods in health technology assessment: a review. [11134920] Health Technol Assess 4(38): 1-130 (2000)
2000 195	An introduction to statistical methods for health technology assessment. [10944742] Health Technol Assess 4(8): i-iv, 1-59 (2000)
1999 196	Factors that limit the quality, number and progress of randomised controlled trials. [10683591] Health Technol Assess 3(20): 1-143 (1999)
1998 197	Systematic reviews of trials and other studies. [10347832] Health Technol Assess 2(19): 1-276 (1998)
1998 198	Qualitative research methods in health technology assessment: a review of the literature. [9919458] Health Technol Assess 2(16): iii-ix, 1-274 (1998)
1998 199	Choosing between randomised and non-randomised studies: a systematic review. [9793791] Health Technol Assess 2(13): i-iv, 1-124 (1998)
1998 200	Consensus development methods, and their use in clinical guideline development. [9561895] Health Technol Assess 2(3): i-iv, 1-88 (1998)
2006 201	The (relative) risks of using odds ratios. [16785380] Arch Dermatol 142(6): 761-4 (2006)
2004 202	Statistical significance and clinical relevance: the importance of power in clinical trials in dermatology. [15611433] Arch Dermatol 140(12): 1520-3 (2004)
2004 203	Hazard ratio in clinical trials. [15273082] Antimicrob Agents Chemother 48(8): 2787-92 (2004)
1990 204	Statistical methods in microbiology. [2200604] Clin Microbiol Rev 3(3): 219-26 (1990)
2008 205	Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. [19018610] Clin Infect Dis 47 Suppl 3(-): S249-65 (2008)
2008 206	Issues in noninferiority trials: the evidence in community-acquired pneumonia. [18986275] Clin Infect Dis 47 Suppl 3(-): S108-20 (2008)
2005 207	Basic statistical considerations in virological experiments. [15613294] J Virol 79(2): 669-76 (2005)
1991 208	Statistical methods applied in microbiology and epidemiology. [1752296] Epidemiol Infect 107(3): 467-78 (1991)
2009 209	Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. [19210357] Allergy 64(5): 669-77 (2009)
2002 210	Statistical issues--significantly important in medical research. [11929408] Allergy 57(2): 76-82 (2002)
2003 211	Review of the use of statistics in infection and immunity. [14638751] Infect Immun 71(12): 6689-92 (2003)
2007 212	A guide to modern statistical analysis of immunological data. [17963513] BMC Immunol 8(-): 27 (2007)
1999 213	Study design and hypothesis testing: issues in the evaluation of evidence from research in nutritional epidemiology. [10359232] Am J Clin Nutr 69(6): 1315S-1321S (1999)
1997 214	Statistical design of calibration studies. [9094919] Am J Clin Nutr 65(4 Suppl): 1187S-1189S (1997)
1997 215	Regression calibration method for correcting measurement-error bias in nutritional epidemiology. [9094918] Am J Clin Nutr 65(4 Suppl): 1179S-1186S (1997)
2007 216	Time-dependent spectral analysis of epidemiological time-series with wavelets. [17301013] J R Soc Interface 4(15): 625-36 (2007)
2008 217	Use of game-theoretical methods in biochemistry and biophysics. [19669489] J Biol Phys 34(1-2): 1-17 (2008)
2007 218	Computing power in case-control association studies through the use of quadratic approximations: application to meta-statistics. [17032289] Ann Hum Genet 71(Pt 2): 262-70 (2007)
2009 219	Factor-analytic models for genotype x environment type problems and structured covariance matrices. [19284520] Genet Sel Evol 41(-): 21 (2009)
2008 220	Parameter expansion for estimation of reduced rank covariance matrices. [18096112] Genet Sel Evol 40(1): 3-24 (2008)
2007 221	Analysis of the real EADGENE data set: multivariate approaches and post analysis (open access publication). [18053574] Genet Sel Evol 39(6): 651-68 (2007)
2007 222	Analysis of the real EADGENE data set: comparison of methods and guidelines for data normalisation and selection of differentially expressed genes (open access publication). [18053573] Genet Sel Evol 39(6): 633-50 (2007)
2007 223	The EADGENE Microarray Data Analysis Workshop (open access publication). [18053572] Genet Sel Evol 39(6): 621-31 (2007)
2008 224	The role of causal reasoning in understanding Simpson's paradox, Lord's paradox, and the suppression effect: covariate selection in the analysis of observational studies. [18302750] Emerg Themes Epidemiol 5(-): 5 (2008)
1994 225	Survey of methods and statistical models used in the analysis of occupational cohort studies. [8000487] Occup Environ Med 51(10): 649-55 (1994)
2009 226	Epidemiological methods to tackle causal questions. [19052115] Int J Epidemiol 38(1): 3-6 (2009)
2009 227	Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. [18824466] Int J Epidemiol 38(1): 287-98 (2009)
2008 228	Analysis of 2 x 2 tables of frequencies: matching test to experimental design. [18710887] Int J Epidemiol 37(6): 1430-5 (2008)
2007 229	Bayesian perspectives for epidemiological research. II. Regression analysis. [17329317] Int J Epidemiol 36(1): 195-202 (2007)
2006 230	Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. [17148467] Int J Epidemiol 35(6): 1570-8 (2006)
2005 231	Regression models for twin studies: a critical review. [16087687] Int J Epidemiol 34(5): 1089-99 (2005)
2005 232	Commentary: Empirical evidence of attrition bias in clinical trials. [15649954] Int J Epidemiol 34(1): 87-8 (2005)
2005 233	Investigating patient exclusion bias in meta-analysis. [15561753] Int J Epidemiol 34(1): 79-87 (2005)
2005 234	Regression to the mean: what it is and how to deal with it. [15333621] Int J Epidemiol 34(1): 215-20 (2005)
2005 235	Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes. [15333619] Int J Epidemiol 34(1): 89-99 (2005)
2004 236	Mendelian randomization: prospects, potentials, and limitations. [15075143] Int J Epidemiol 33(1): 30-42 (2004)
2002 237	Probabilistic record linkage and a method to calculate the positive predictive value. [12540730] Int J Epidemiol 31(6): 1246-52 (2002)
2002 238	An overview of relations among causal modelling methods. [12435780] Int J Epidemiol 31(5): 1030-7 (2002)
2002 239	Direction and impact of language bias in meta-analyses of controlled trials: empirical study. [11914306] Int J Epidemiol 31(1): 115-23 (2002)
2002 240	Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction. [11914302] Int J Epidemiol 31(1): 96-104 (2002)
2002 241	Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. [11914301] Int J Epidemiol 31(1): 88-95 (2002)
2002 242	Commentary: improving pooled analyses in epidemiology. [11914300] Int J Epidemiol 31(1): 86-7 (2002)
2002 243	Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. [11914297] Int J Epidemiol 31(1): 72-6 (2002)
2001 244	Capture-recapture methods--useful or misleading? [11171841] Int J Epidemiol 30(1): 12-4 (2001)
1999 245	Simple sample size calculation for cluster-randomized trials. [10342698] Int J Epidemiol 28(2): 319-26 (1999)
1998 246	A review of statistical methods for estimating the risk of vertical human immunodeficiency virus transmission. [10024204] Int J Epidemiol 27(6): 1064-7 (1998)
1997 247	Regression models for ordinal responses: a review of methods and applications. [9447413] Int J Epidemiol 26(6): 1323-33 (1997)
1997 248	On the use of causal criteria. [9447391] Int J Epidemiol 26(6): 1137-41 (1997)
2009 249	The quality of meta-analyses of genetic association studies: a review with recommendations. [19901000] Am J Epidemiol 170(11): 1333-43 (2009)
2009 250	Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. [19498075] Am J Epidemiol 170(3): 269-79 (2009)
2009 251	Type of alcoholic beverage and risk of head and neck cancer--a pooled analysis within the INHANCE Consortium. [19064644] Am J Epidemiol 169(2): 132-42 (2009)
2008 252	Combining matched and unmatched control groups in case-control studies. [18836151] Am J Epidemiol 168(10): 1204-10 (2008)
2008 253	Effect of formal statistical significance on the credibility of observational associations. [18611956] Am J Epidemiol 168(4): 374-83; discussion 384-90 (2008)
2007 254	Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. [17712019] Am J Epidemiol 166(10): 1203-9 (2007)
2007 255	Turning the pump handle: evolving methods for integrating the evidence on gene-disease association. [17804859] Am J Epidemiol 166(8): 863-6 (2007)
2006 256	Bias in clinical intervention research. [16443796] Am J Epidemiol 163(6): 493-501 (2006)
2006 257	Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. [16410347] Am J Epidemiol 163(5): 397-403 (2006)
2006 258	Statistical issues in life course epidemiology. [16306313] Am J Epidemiol 163(1): 84-96 (2006)
2005 259	Interrater reliability: completing the methods description in medical records review studies. [15870162] Am J Epidemiol 161(10): 974-7 (2005)
2004 260	Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. [15105181] Am J Epidemiol 159(9): 882-90 (2004)
2002 261	Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. [12181099] Am J Epidemiol 156(4): 300-10 (2002)
2000 262	Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. [11092432] Am J Epidemiol 152(10): 908-11; discussion 912 (2000)
2000 263	Bias in the evaluation of low-magnitude associations: an empirical perspective. [10853631] Am J Epidemiol 151(10): 939-45 (2000)
2000 264	Problems due to small samples and sparse data in conditional logistic regression analysis. [10707923] Am J Epidemiol 151(5): 531-9 (2000)
1999 265	Random-effects meta-analyses are not always conservative. [10472946] Am J Epidemiol 150(5): 469-75 (1999)
1999 266	Invited commentary: propensity scores. [10453808] Am J Epidemiol 150(4): 327-33 (1999)
1999 267	Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. [10412966] Am J Epidemiol 150(2): 206-15 (1999)
1999 268	Presenting statistical uncertainty in trends and dose-response relations. [10369501] Am J Epidemiol 149(12): 1077-86 (1999)
1998 269	Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example. [9508109] Am J Epidemiol 147(4): 407-13 (1998)
1997 270	Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. [9149663] Am J Epidemiol 145(10): 917-25 (1997)
2003 271	Matched cohort methods for injury research. [12923989] Epidemiol Rev 25(-): 43-50 (2003)
2002 272	Beyond intention to treat. [12119861] Epidemiol Rev 24(1): 85-90 (2002)
2002 273	Community-based health intervention trials: an overview of methodological issues. [12119859] Epidemiol Rev 24(1): 72-9 (2002)
2002 274	Special issues related to randomized trials of primary prevention. [12119858] Epidemiol Rev 24(1): 67-71 (2002)
2002 275	Ethics in the design and conduct of clinical trials. [12119856] Epidemiol Rev 24(1): 54-8 (2002)
2002 276	Design of randomized trials. [12119855] Epidemiol Rev 24(1): 4-11 (2002)
2002 277	Sample size calculations for randomized controlled trials. [12119854] Epidemiol Rev 24(1): 39-53 (2002)
2002 278	Analysis of randomized controlled trials. [12119853] Epidemiol Rev 24(1): 26-38 (2002)
2002 279	Management and conduct of randomized controlled trials. [12119852] Epidemiol Rev 24(1): 12-25 (2002)
2000 280	Statistics. [10939017] Epidemiol Rev 22(1): 126-30 (2000)
1999 281	Spatial analytical methods and geographic information systems: use in health research and epidemiology. [10682254] Epidemiol Rev 21(2): 143-61 (1999)
1999 282	Design and interpretation of vaccine field studies. [10520474] Epidemiol Rev 21(1): 73-88 (1999)
1999 283	Use of the case-control approach in vaccine evaluation: efficacy and adverse effects. [10520473] Epidemiol Rev 21(1): 56-72 (1999)
1999 284	Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today. [10520470] Epidemiol Rev 21(1): 7-23 (1999)
1998 285	New techniques for the analysis of cohort studies. [9762515] Epidemiol Rev 20(1): 122-34 (1998)
1998 286	Use of computerized record linkage in cohort studies. [9762514] Epidemiol Rev 20(1): 112-21 (1998)
1998 287	Growth and development of term children born with low birth weight: effects of genetic and environmental factors. [9672513] J Pediatr 133(1): 67-72 (1998)
1998 288	Approaches for conducting large cohort studies. [9762512] Epidemiol Rev 20(1): 91-9 (1998)
1998 289	Population-based cohort studies. [9762511] Epidemiol Rev 20(1): 81-90 (1998)
1998 290	Quality assurance and quality control in longitudinal studies. [9762510] Epidemiol Rev 20(1): 71-80 (1998)
1998 291	Retaining and tracking cohort study members. [9762509] Epidemiol Rev 20(1): 57-70 (1998)
1998 292	Exposure measurement in cohort studies: the challenges of prospective data collection. [9762508] Epidemiol Rev 20(1): 43-56 (1998)
1998 293	Methodological issues for biomarkers and intermediate outcomes in cohort studies. [9762507] Epidemiol Rev 20(1): 29-42 (1998)
1998 294	Outcomes in cohort studies. [9762506] Epidemiol Rev 20(1): 15-28 (1998)
1997 295	Ethical and legal issues in genetic epidemiology. [9360913] Epidemiol Rev 19(1): 163-74 (1997)
1997 296	DNA banking in epidemiologic studies. [9360912] Epidemiol Rev 19(1): 156-62 (1997)
1997 297	Population studies of allele frequencies in single gene disorders: methodological and policy considerations. [9360902] Epidemiol Rev 19(1): 52-60 (1997)
1997 298	Evolving methods in genetic epidemiology. IV. Approaches to non-Mendelian inheritance. [9360901] Epidemiol Rev 19(1): 44-51 (1997)
1997 299	Evolving methods in genetic epidemiology. III. Gene-environment interaction in epidemiologic research. [9360900] Epidemiol Rev 19(1): 33-43 (1997)
2003 300	Number needed to treat (NNT): implication in rheumatology clinical practice. [12634229] Ann Rheum Dis 62(4): 316-21 (2003)
2004 301	A surplus of positive trials: weighing biases and reconsidering equipoise. [15142261] Arthritis Res Ther 6(3): 117-9 (2004)
2008 302	Systematic review and meta-analysis: when one study is just not enough. [18178786] Clin J Am Soc Nephrol 3(1): 253-60 (2008)
2007 303	Practice recommendations based on low, very low, and missing evidence. [17699379] Clin J Am Soc Nephrol 2(1): 11-2 (2007)
2009 304	Reporting results of orthopaedic research: confidence intervals and p values. [19565303] Clin Orthop Relat Res 467(10): 2736-7 (2009)
1993 305	What price inconclusive clinical trials? [8323204] Ann R Coll Surg Engl 75(3): 145-6 (1993)
2004 306	Users' guide to the surgical literature: how to use a systematic literature review and meta-analysis. [14997929] Can J Surg 47(1): 60-7 (2004)
2002 307	Users' guide to the surgical literature: how to use an article reporting population-based volume-outcome relationships in surgery. [11939652] Can J Surg 45(2): 109-15 (2002)
2007 308	Is MEDLINE alone enough for a meta-analysis? [17555429] Aliment Pharmacol Ther 26(1): 125-6; author reply 126 (2007)
2008 309	Case-control study design: what, when, and why? [19057257] J Thorac Oncol 3(12): 1371-2 (2008)
2007 310	The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. [17431101] Mol Cancer Ther 6(4): 1180-5 (2007)
2002 311	Novel endpoints and design of early clinical trials. [12401680] Ann Oncol 13 Suppl 4(-): 139-43 (2002)
2002 312	Designing randomised trials: both large and small trials are needed. [12401679] Ann Oncol 13 Suppl 4(-): 131-8 (2002)
2002 313	Evaluation of response: new and standard criteria. [12401678] Ann Oncol 13 Suppl 4(-): 127-9 (2002)
2003 314	Survival analysis part IV: further concepts and methods in survival analysis. [12942105] Br J Cancer 89(5): 781-6 (2003)
2003 315	Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit. [12915864] Br J Cancer 89(4): 605-11 (2003)
2003 316	Survival analysis part I: basic concepts and first analyses. [12865907] Br J Cancer 89(2): 232-8 (2003)
1996 317	Multistage designs for phase II clinical trials: statistical issues in cancer research. [8883425] Br J Cancer 74(8): 1317-20 (1996)
1995 318	Sample size: how many patients are necessary? [7599035] Br J Cancer 72(1): 1-9 (1995)
1993 319	Intention to treat--who should use ITT? [8398686] Br J Cancer 68(4): 647-50 (1993)
1993 320	Surrogate endpoints. [8353034] Br J Cancer 68(3): 457-9 (1993)
1993 321	Current statistical issues in clinical cancer research. [8353033] Br J Cancer 68(3): 455-6 (1993)
2008 322	Systematic review of statistical methods used in molecular marker studies in cancer. [18320601] Cancer 112(8): 1862-8 (2008)
2008 323	Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. [18008363] Cancer 112(2): 228-42 (2008)
2007 324	The hazards of intermediate endpoints. [17849427] Cancer 110(9): 1877-9 (2007)
2007 325	Risks and benefits associated with novel phase 1 oncology trial designs. [17628485] Cancer 110(5): 1115-24 (2007)
2002 326	Current concepts in radiation enteritis and implications for future clinical trials. [12209703] Cancer 95(5): 1151-63 (2002)
2009 327	Monitoring for lack of benefit: a critical component of a randomized clinical trial. [19064977] J Clin Oncol 27(4): 629-33 (2009)
2009 328	Considerations for the use of imaging tools for phase II treatment trials in oncology. [19276276] Clin Cancer Res 15(6): 1891-7 (2009)
2009 329	Randomized phase II designs. [19276275] Clin Cancer Res 15(6): 1883-90 (2009)
2009 330	Effective incorporation of biomarkers into phase II trials. [19276274] Clin Cancer Res 15(6): 1898-905 (2009)
2009 331	Alternate endpoints for screening phase II studies. [19276273] Clin Cancer Res 15(6): 1873-82 (2009)
2009 332	Novel designs and end points for phase II clinical trials. [19276272] Clin Cancer Res 15(6): 1866-72 (2009)
2008 333	The ethics of phase 0 oncology trials. [18559585] Clin Cancer Res 14(12): 3692-7 (2008)
2008 334	Phase 0 trials: an industry perspective. [18559583] Clin Cancer Res 14(12): 3683-8 (2008)
2008 335	The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials. [18559580] Clin Cancer Res 14(12): 3664-9 (2008)
2007 336	Trends in the use and role of biomarkers in phase I oncology trials. [18006773] Clin Cancer Res 13(22 Pt 1): 6719-26 (2007)
2007 337	Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? [18006752] Clin Cancer Res 13(22 Pt 1): 6545-8 (2007)
2002 338	Biostatistical approaches for modeling longitudinal and event time data. [12171871] Clin Cancer Res 8(8): 2473-4 (2002)
1997 339	The scientific basis of clinical trials: statistical aspects. [9815661] Clin Cancer Res 3(12 Pt 2): 2587-90 (1997)
2009 340	Dose escalation methods in phase I cancer clinical trials. [19436029] J Natl Cancer Inst 101(10): 708-20 (2009)
1999 341	Incremental costs of enrolling cancer patients in clinical trials: a population-based study. [10340904] J Natl Cancer Inst 91(10): 847-53 (1999)
2008 342	The clinical significance of statistical significance. [18984874] Oncologist 13(11): 1129-33 (2008)
2009 343	Editorial on hypothesis and objectives in clinical trials: superiority, equivalence and non-inferiority. [19302714] Thromb J 7(-): 3 (2009)
1997 344	Tyranny of the p-value: the conflict between statistical significance and common sense. [9042074] J Dent Res 76(1): 534-6 (1997)
1990 345	Statistical management of data in clinical research. [2101261] Crit Rev Oral Biol Med 1(1): 55-66 (1990)
2005 346	Synthesizing medical evidence: systematic reviews and metaanalyses. [16241107] Neurosurg Focus 19(4): E5 (2005)
2008 347	When is a negative phase II trial truly negative? [18755930] Am J Respir Crit Care Med 178(6): 554-5 (2008)
2004 348	The ethical conduct of clinical research involving critically ill patients in the United States and Canada: principles and recommendations. [15590885] Am J Respir Crit Care Med 170(12): 1375-84 (2004)
2004 349	Positive clinical trials: understand the control group before implementing the result. [15151921] Am J Respir Crit Care Med 170(3): 223-6 (2004)
1998 350	Number needed to treat and relative risk reduction. [9424990] Ann Intern Med 128(1): 72-3 (1998)
1995 351	Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. [7486471] Ann Intern Med 123(11): 873-7 (1995)
2005 352	Understanding systematic reviews and meta-analysis. [16040886] Arch Dis Child 90(8): 845-8 (2005)
2004 353	GRADE: levels of evidence and grades of recommendation. [15102650] Arch Dis Child 89(5): 489 (2004)
1995 354	Statistics from the inside. 16. Multiple regression (2). [7492177] Arch Dis Child 73(3): 270-4 (1995)
1994 355	Statistics from the inside. 13. Probability and decisions. [8067802] Arch Dis Child 71(1): 90-4 (1994)
1993 356	10. Counted data (2). [8333779] Arch Dis Child 68(6): 800-2 (1993)
1993 357	Counted data (1). [8481051] Arch Dis Child 68(2): 246-9 (1993)
1992 358	Statistics from the inside. 7. Regression and correlation. [1444537] Arch Dis Child 67(10): 1306-9 (1992)
1992 359	Statistics from the inside. 6. Data structures (continued). [1626999] Arch Dis Child 67(6): 757-9 (1992)
2007 360	Documenting research in scientific articles: Guidelines for authors: 3. Reporting multivariate analyses. [17296672] Chest 131(2): 628-32 (2007)
2007 361	Documenting research in scientific articles: guidelines for authors: 2. Reporting hypothesis tests. [17218594] Chest 131(1): 317-9 (2007)
2006 362	Documenting research in scientific articles: guidelines for authors: reporting research designs and activities. [17035466] Chest 130(4): 1263-8 (2006)
2002 363	The design of randomized clinical trials in critically ill patients. [11948065] Chest 121(4): 1290-300 (2002)
2000 364	Reality and meta-analyses. [10988210] Chest 118(3): 835-6 (2000)
2000 365	Is meta-analysis a metaphysical or a scientific method? [10988209] Chest 118(3): 832-4 (2000)
1999 366	Is meta-analysis really meta-physics? [10453885] Chest 116(2): 539-42 (1999)
2002 367	Advice on statistical analysis for Circulation Research. [12386142] Circ Res 91(8): 662-71 (2002)
2008 368	A primer in longitudinal data analysis. [18981315] Circulation 118(19): 2005-10 (2008)
2008 369	Some old and some new statistical tools for outcomes research. [18711024] Circulation 118(8): 872-84 (2008)
2008 370	Survival methods: additional topics. [18519862] Circulation 117(22): 2949-55 (2008)
2008 371	Methods and limitations of assessing new noninvasive tests: Part II: Outcomes-based validation and reliability assessment of noninvasive testing. [18506018] Circulation 117(21): 2793-801 (2008)
2008 372	Methods and limitations of assessing new noninvasive tests: part I: Anatomy-based validation of noninvasive testing. [18490536] Circulation 117(20): 2684-90 (2008)
2008 373	Logistic regression. [18458181] Circulation 117(18): 2395-9 (2008)
2008 374	Multiple linear regression: accounting for multiple simultaneous determinants of a continuous dependent variable. [18378626] Circulation 117(13): 1732-7 (2008)
2008 375	Analysis of variance. [18172051] Circulation 117(1): 115-21 (2008)
2007 376	Association studies in an era of too much information: clinical analysis of new biomarker and genetic data. [17965399] Circulation 116(17): 1866-70 (2007)
2007 377	What exactly do the trends mean? [17893285] Circulation 116(13): 1437-9 (2007)
2007 378	Meta-analysis. [17548743] Circulation 115(22): 2870-5 (2007)
2007 379	Evaluation of randomized controlled trials. [17404173] Circulation 115(13): 1819-22 (2007)
2007 380	Design of randomized controlled trials. [17339574] Circulation 115(9): 1164-9 (2007)
2007 381	Use and misuse of the receiver operating characteristic curve in risk prediction. [17309939] Circulation 115(7): 928-35 (2007)
2007 382	Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. [17283280] Circulation 115(5): 654-7 (2007)
2007 383	Survival methods. [17200454] Circulation 115(1): 109-13 (2007)
2006 384	Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation. [16365198] Circulation 113(3): 456-62 (2006)
2004 385	The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. [15173053] Circulation 109(21): e305-7 (2004)
2004 386	The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design. [15173052] Circulation 109(21): e302-4 (2004)
2008 387	Interpreting results of clinical trials: a conceptual framework. [18728215] Clin J Am Soc Nephrol 3(5): 1246-52 (2008)
2006 388	Cohort studies: marching forward. [17699334] Clin J Am Soc Nephrol 1(5): 1117-23 (2006)
2006 389	The meta-analysis: supportive or illuminating? [17107979] Eur Heart J 27(23): 2744-5 (2006)
2006 390	Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials. [16870690] Eur Heart J 27(18): 2158-64 (2006)
2006 391	Limitations of analyses of effectiveness using observational data. [16785246] Eur Heart J 27(14): 1642-3 (2006)
2004 392	Interpretation of observational studies. [15253985] Heart 90(8): 956-60 (2004)
2001 393	Absolute, attributable, and relative risk in the management of coronary heart disease. [11302989] Heart 85(5): 491-2 (2001)
2005 394	Statistical issues in the analysis of neuronal data. [15985692] J Neurophysiol 94(1): 8-25 (2005)
2007 395	The Bayesian clinician. [18097119] J Postgrad Med 53(4): 267-9 (2007)
1993 396	Statistics in medical research--III. Correlation and regression analysis. [7996506] J Postgrad Med 39(4): 235-43 (1993)
2007 397	Data extraction errors in meta-analyses that use standardized mean differences. [17652297] JAMA 298(4): 430-7 (2007)
2002 398	How statistical expertise is used in medical research. [12038922] JAMA 287(21): 2817-20 (2002)
2001 399	Comparison of evidence of treatment effects in randomized and nonrandomized studies. [11497536] JAMA 286(7): 821-30 (2001)
1998 400	Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. [9676681] JAMA 280(3): 278-80 (1998)
1998 401	Meta-analysis as a clinical tool in nephrology. [9551387] Kidney Int 53(4): 819-25 (1998)
2008 402	Clinical research of kidney diseases IV: Standard regression models. [18182407] Nephrol Dial Transplant 23(2): 475-82 (2008)
2007 403	P less than .05: what does it really mean? [17332213] Pediatrics 119(3): 608-10 (2007)
2002 404	Data and models determine treatment proposals--an illustration from meta-analysis. [11884693] Postgrad Med J 78(917): 131-4 (2002)
2001 405	Balancing statistical and clinical significance in evaluating treatment effects. [11222834] Postgrad Med J 77(905): 201-4 (2001)
1998 406	Statistics in medicine: some considerations from a clinician's point of view. [10211346] Postgrad Med J 74(876): 577-8 (1998)
2000 407	Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies. [10662865] Rheumatology (Oxford) 39(1): 1-2 (2000)
2005 408	When should you use statistics? [16059787] Swiss Med Wkly 135(23-24): 337-8 (2005)
2003 409	Statistics in medical research. [14655052] Swiss Med Wkly 133(39-40): 522-9 (2003)
2003 410	Statistics in medicine. [14655051] Swiss Med Wkly 133(39-40): 521 (2003)
1991 411	Statistics in respiratory medicine. 3. Scale, parametric methods, and transformations. [1877042] Thorax 46(7): 536-8 (1991)
1991 412	Statistics in respiratory medicine. 2. Repeatability and method comparison. [1858087] Thorax 46(6): 454-6 (1991)
2005 413	A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints. [15483190] Toxicol Sci 84(1): 167-85 (2005)
2001 414	Statistical issues in the analysis of low-dose endocrine disruptor data. [11353128] Toxicol Sci 61(2): 201-10 (2001)
2006 415	Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. [17058242] Hepatology 44(5): 1075-82 (2006)
1996 416	Meta-analysis: an introduction and point of view. [8666350] Hepatology 23(4): 917-28 (1996)
2008 417	Meta-analysis. [18617074] J Am Coll Cardiol 52(3): 237-8 (2008)
2004 418	Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. [15172393] J Am Coll Cardiol 43(11): 1929-39 (2004)
2007 419	The radiology task: Bayesian theory and perception. [17510249] Br J Radiol 80(954): 389-91 (2007)
2007 420	Visual grading characteristics (VGC) analysis: a non-parametric rank-invariant statistical method for image quality evaluation. [16854962] Br J Radiol 80(951): 169-76 (2007)
2004 421	Randomized controlled trials. [15547188] AJR Am J Roentgenol 183(6): 1539-44 (2004)
2002 422	Statistically engineering the study for success. [12076904] AJR Am J Roentgenol 179(1): 47-52 (2002)
1988 423	Statistical techniques for medical decision making: applications to diagnostic radiology. [3126627] AJR Am J Roentgenol 150(4): 745-50 (1988)
2000 424	Randomized controlled trials are not appropriate for imaging technology evaluation. [10914899] J Nucl Med 41(7): 1125-6 (2000)
1998 425	Statistical analysis: the need, the concept, and the usage. [9707849] Indian J Ophthalmol 46(1): 51-8 (1998)
1996 426	Assessment of clinical significance: the number needed to treat. [8916601] Indian J Ophthalmol 44(2): 113-5 (1996)
2006 427	How to make clinical decisions from statistics. [16637974] Clin Exp Optom 89(3): 176-83 (2006)
2008 428	Statistics: understanding the jargon. [19198545] Bull Soc Belge Ophtalmol -(309-310): 7-9 (2008)
2005 429	Epidemiology for ophthalmologists: an introduction to concepts, study designs, and interpreting findings. [15722322] Br J Ophthalmol 89(3): 378-84 (2005)
2002 430	The determination of sample size in controlled clinical trials in ophthalmology. [12185110] Br J Ophthalmol 86(9): 946-7 (2002)
2009 431	Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. [19654195] CMAJ 181(8): 488-93 (2009)
2008 432	Ethics guidelines for clinical trials to be revised. [18195278] CMAJ 178(2): 138 (2008)
2007 433	The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. [17420491] CMAJ 176(8): 1091-6 (2007)
2004 434	Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. [15313996] CMAJ 171(4): 353-8 (2004)
2001 435	Intention-to-treat principle. [11760981] CMAJ 165(10): 1339-41 (2001)
1995 436	Basic statistics for clinicians: 1. Hypothesis testing. [7804919] CMAJ 152(1): 27-32 (1995)
1989 437	Confidence intervals: from statistical significance to clinical significance. [2804844] CMAJ 141(9): 881-3 (1989)
2003 438	Special Topics III: bias. [14593188] Radiology 229(3): 617-21 (2003)
1999 439	Statistical methods for comparative qualitative analysis. [10352580] Radiology 211(3): 605-7 (1999)
2006 440	The value of a P value. [16908545] AJNR Am J Neuroradiol 27(7): 1389-90 (2006)
2002 441	N-of-1 randomized controlled trials ('N-of-1 trials'): singularly useful in geriatric medicine. [12147558] Age Ageing 31(4): 227-32 (2002)
2010 442	Recruitment and retention of patients into emergency medicine clinical trials. [21040112] Acad Emerg Med 17(10): 1104-12 (2010)
2005 443	Fundamental steps in experimental design for animal studies. [15810459] Acta Cir Bras 20(1): 2-8 (2005)
2008 444	Clinical research on new drugs (Phase I). Profile of scientific publications: data from the pre-clinical phase and bioethical aspects. [19030752] Acta Cir Bras 23(6): 531-5 (2008)
2009 445	Pitfalls in the design and analysis of paediatric clinical trials: a case of a 'failed' multi-centre study, and potential solutions. [18826493] Acta Paediatr 98(2): 385-91 (2009)
2011 446	Mixed method designs in implementation research. [20967495] Adm Policy Ment Health 38(1): 44-53 (2011)
2011 447	How helpful are meta-analyses in determining the best therapy of blood diseases? [21150191] Acta Haematol 125(1-2): 91-101 (2011)
2010 448	Investigator-initiated trials of targeted oncology agents: why independent research is at risk? [20133383] Ann Oncol 21(8): 1573-8 (2010)
2010 449	Looking for efficiency rather than efficacy in randomized controlled trials in oncology. [20501504] Ann Oncol 21(7): 1391-3 (2010)
2004 450	Statistical analyses of repeated measures in physiological research: a tutorial. [14973047] Adv Physiol Educ 28(1-4): 2-14 (2004)
2004 451	Analogies for understanding statistics. [15319195] Adv Physiol Educ 28(1-4): 124-5 (2004)
2008 452	Explorations in statistics: standard deviations and standard errors. [18794241] Adv Physiol Educ 32(3): 203-8 (2008)
2007 453	Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? [17934093] Ann Rheum Dis 66 Suppl 3(-): iii40-1 (2007)
2004 454	Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. [15286014] Am J Epidemiol 160(4): 301-5 (2004)
2004 455	Imputations of missing values in practice: results from imputations of serum cholesterol in 28 cohort studies. [15229115] Am J Epidemiol 160(1): 34-45 (2004)
2008 456	Use of multiple imputation in the epidemiologic literature. [18591202] Am J Epidemiol 168(4): 355-7 (2008)
2004 457	New applications of statistical tools in plant pathology. [18943077] Phytopathology 94(9): 999-1003 (2004)
2009 458	Design and debugging databases for statistical analysis. [19445866] Allergol Immunopathol (Madr) 37(2): 93-7 (2009)
2008 459	Issues related to the conduct of systematic reviews: a focus on the nutrition field. [18996852] Am J Clin Nutr 88(5): 1191-9 (2008)
2010 460	GRACE principles: recognizing high-quality observational studies of comparative effectiveness. [20560690] Am J Manag Care 16(6): 467-71 (2010)
2004 461	Systematic reviews for evidence-based management: how to find them and what to do with them. [15623270] Am J Manag Care 10(11 Pt 1): 806-12 (2004)
2002 462	Designing studies to ensure that estimates of test accuracy are transferable. [11895830] BMJ 324(7338): 669-71 (2002)
2002 463	What to do about poor clinical performance in clinical trials. [11850378] BMJ 324(7334): 419-20 (2002)
2002 464	Peer review of statistics in medical research: the other problem. [12028986] BMJ 324(7348): 1271-3 (2002)
2011 465	Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. [21878462] BMJ 343(-): d4829 (2011)
2004 466	What doesn't work and how to show it. [14988162] BMJ 328(7438): 473 (2004)
2004 467	Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery. [15514356] BMJ 329(7473): 1039-42 (2004)
2003 468	Strategy for randomised clinical trials in rare cancers. [12842959] BMJ 327(7405): 47-9 (2003)
2003 469	Ethics of clinical trials from a bayesian and decision analytic perspective: whose equipoise is it anyway? [12727776] BMJ 326(7396): 980-1 (2003)
2007 470	Uncertainty in heterogeneity estimates in meta-analyses. [17974687] BMJ 335(7626): 914-6 (2007)
2009 471	Written informed consent and selection bias in observational studies using medical records: systematic review. [19282440] BMJ 338(-): b866 (2009)
2005 472	Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. [15681569] BMJ 330(7494): 753 (2005)
2005 473	Standard deviations and standard errors. [16223828] BMJ 331(7521): 903 (2005)
2008 474	Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. [18316340] BMJ 336(7644): 601-5 (2008)
2006 475	Further lessons from the TGN1412 tragedy. [16888292] BMJ 333(7562): 270-1 (2006)
2009 476	What can we learn from design faults in the Women's Health Initiative randomized clinical trial? [19583558] Bull NYU Hosp Jt Dis 67(2): 226-9 (2009)
2009 477	Methods to analyze real-world databases and registries. [19583553] Bull NYU Hosp Jt Dis 67(2): 193-7 (2009)
2008 478	Some main problems eroding the credibility and relevance of randomized trials. [18537784] Bull NYU Hosp Jt Dis 66(2): 135-9 (2008)
2008 479	How to do human-subjects research if you do not have an institutional review board. [18812001] Respir Care 53(10): 1362-7 (2008)
2008 480	Practical tips for working effectively with your institutional review board. [18812000] Respir Care 53(10): 1354-61 (2008)
2008 481	Institutional review board consideration of chart reviews, case reports, and observational studies. [18811999] Respir Care 53(10): 1350-3 (2008)
2008 482	Protecting vulnerable subjects in clinical research: children, pregnant women, prisoners, and employees. [18811998] Respir Care 53(10): 1342-9 (2008)
2008 483	Informed consent: what is it? Who can give it? How do we improve it? [18811997] Respir Care 53(10): 1337-41 (2008)
2008 484	The purpose, composition, and function of an institutional review board: balancing priorities. [18811996] Respir Care 53(10): 1330-6 (2008)
2008 485	The historical, ethical, and legal background of human-subjects research. [18811995] Respir Care 53(10): 1325-9 (2008)
2008 486	The institutional review board and you. [18811994] Respir Care 53(10): 1324 (2008)
2009 487	Translating evidence into practice. [19796420] Respir Care 54(10): 1386-401 (2009)
2008 488	Dispelling the myths: calling for sex-specific reporting of trial results. [18452679] Mayo Clin Proc 83(5): 523-5 (2008)
2011 489	Review and classification of variability analysis techniques with clinical applications. [21985357] Biomed Eng Online 10(-): 90 (2011)
2011 490	A note on the use of the generalized odds ratio in meta-analysis of association studies involving bi- and tri-allelic polymorphisms. [21645382] BMC Res Notes 4(-): 172 (2011)
2009 491	Optimizing trial design: sequential, adaptive, and enrichment strategies. [19188520] Circulation 119(4): 597-605 (2009)
2003 492	An appraisal of multivariable logistic models in the pulmonary and critical care literature. [12628895] Chest 123(3): 923-8 (2003)
2008 493	From Delphi to knowledge and comfort: the devil is in the details. [18460509] Chest 133(5): 1060-2 (2008)
2003 494	Correlation and simple linear regression. [12773666] Radiology 227(3): 617-22 (2003)
2008 495	Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. [18349026] Eur Heart J 29(9): 1086-92 (2008)
2009 496	Need for ethics approval and patient consent in clinical research. [19286586] Stroke 40(5): 1555-6 (2009)
2007 497	Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. [17272767] Stroke 38(3): 1091-6 (2007)
2006 498	How to design a clinical in cardiology. The main issues. [16623360] Rev Port Cardiol 25(1): 105-18 (2006)
2006 499	Types of clinical studies. Systematic reviews. [16673653] Rev Port Cardiol 25(2): 233-46 (2006)
2002 500	Subgroup analysis in therapeutic trials. [12017805] Rev Port Cardiol 21(3): 339-46 (2002)
2002 501	Basics of methodologic analysis of therapeutic trials. Part I: Validity of the results. [12090131] Rev Port Cardiol 21(4): 457-69 (2002)
2002 502	Intention-to-treat analysis in clinical trials: principles and practical importance. [12522981] Rev Port Cardiol 21(10): 1191-8 (2002)
2004 503	Randomization methods in clinical trials. [15279458] Rev Port Cardiol 23(5): 741-55 (2004)
2008 504	Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: Part 2: Randomized controlled trials. [19057624] Pain Physician 11(6): 717-73 (2008)
2005 505	Registering clinical trials. [16850079] Pain Physician 8(3): 249-50 (2005)
2009 506	Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: Part 7: systematic reviews and meta-analyses of diagnostic accuracy studies. [19935980] Pain Physician 12(6): 929-63 (2009)
2003 507	Bayesian computation: a statistical revolution. [14667292] Philos Transact A Math Phys Eng Sci 361(1813): 2681-97 (2003)
2009 508	An overview of recent developments in genomics and associated statistical methods. [19805447] Philos Transact A Math Phys Eng Sci 367(1906): 4313-37 (2009)
2010 509	Development of anti-cancer drugs. [21034677] Discov Med 10(53): 355-62 (2010)
2011 510	Quantifying selective reporting and the Proteus phenomenon for multiple datasets with similar bias. [21479240] PLoS One 6(3): e18362 (2011)
2011 511	GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets. [21365010] PLoS One 6(2): e17259 (2011)
2011 512	Three-armed trials including placebo and no-treatment groups may be subject to publication bias: systematic review. [21655196] PLoS One 6(5): e20679 (2011)
2010 513	Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. [21048948] PLoS One 5(10): e13550 (2010)
2010 514	Obtaining valid laboratory data in clinical trials conducted in resource diverse settings: lessons learned from a microbicide phase III clinical trial. [21048963] PLoS One 5(10): e13592 (2010)
2010 515	A generalized formula for converting chi-square tests to effect sizes for meta-analysis. [20383281] PLoS One 5(4): e10059 (2010)
2007 516	Statistical reviewers improve reporting in biomedical articles: a randomized trial. [17389922] PLoS One 2(3): e332 (2007)
2010 517	Phase III clinical trial development: a process of chutes and ladders. [21062928] Clin Cancer Res 16(22): 5381-9 (2010)
2010 518	Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. [20215542] Clin Cancer Res 16(6): 1726-36 (2010)
2010 519	Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. [20215544] Clin Cancer Res 16(6): 1719-25 (2010)
2010 520	An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. [20215546] Clin Cancer Res 16(6): 1710-8 (2010)
2010 521	GCP data quality for early clinical development. [20215550] Clin Cancer Res 16(6): 1756-63 (2010)
2010 522	The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. [20215557] Clin Cancer Res 16(6): 1764-9 (2010)
2010 523	Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. [20215558] Clin Cancer Res 16(6): 1745-55 (2010)
2007 524	Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. [17289865] Clin Cancer Res 13(3): 781-2 (2007)
2007 525	Phase 0 trials: are they ethically challenged? [17289866] Clin Cancer Res 13(3): 783-4 (2007)
2008 526	Statistical issues in translational cancer research. [18829473] Clin Cancer Res 14(19): 5954-8 (2008)
2010 527	New results will change the paradigm for phase I trials and drug approval. [20930096] Oncologist 15(10): 1023-5 (2010)
2010 528	The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. [20237212] Oncologist 15 Suppl 1(-): 13-8 (2010)
2010 529	Combining targeted therapies: practical issues to consider at the bench and bedside. [20080862] Oncologist 15(1): 37-50 (2010)
2009 530	Bayesian statistics in oncology: a guide for the clinical investigator. [19691089] Cancer 115(23): 5371-81 (2009)
2007 531	Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution. [17879372] Cancer 110(8): 1644-7 (2007)
2009 532	Central pathology review in multicenter trials and studies: lessons from the nephroblastoma trials. [19241454] Cancer 115(9): 1977-83 (2009)
2003 533	Survival analysis part II: multivariate data analysis--an introduction to concepts and methods. [12888808] Br J Cancer 89(3): 431-6 (2003)
2008 534	Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. [18577549] Rheumatology (Oxford) 47(9): 1367-72 (2008)
2008 535	Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. [18495823] Rheumatology (Oxford) 47(7): 1054-7 (2008)
2008 536	Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. [18024533] Clin Chem 54(1): 17-23 (2008)
2010 537	Corticosteroids for sepsis: registry versus Cochrane systematic review! [20727225] Crit Care 14(4): 185 (2010)
2010 538	Delta inflation: a bias in the design of randomized controlled trials in critical care medicine. [20429873] Crit Care 14(2): R77 (2010)
2005 539	Trial registration report card. [16382069] N Engl J Med 353(26): 2809-11 (2005)
2005 540	Registries and registration of clinical trials. [16382070] N Engl J Med 353(26): 2811-2 (2005)
2004 541	Clinical trial registration: a statement from the International Committee of Medical Journal Editors. [15356289] N Engl J Med 351(12): 1250-1 (2004)
2007 542	Statistics in medicine--reporting of subgroup analyses in clinical trials. [18032770] N Engl J Med 357(21): 2189-94 (2007)
2010 543	Sample size calculation in clinical trials: part 13 of a series on evaluation of scientific publications. [20827353] Dtsch Arztebl Int 107(31-32): 552-6 (2010)
2011 544	Survival analysis: part 15 of a series on evaluation of scientific publications. [21475574] Dtsch Arztebl Int 108(10): 163-9 (2011)
2011 545	Randomized controlled trials-an indispensible part of clinical research. [22013493] Dtsch Arztebl Int 108(39): 661-2 (2011)
2010 546	Linear regression analysis: part 14 of a series on evaluation of scientific publications. [21116397] Dtsch Arztebl Int 107(44): 776-82 (2010)
2010 547	The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. [20467553] Dtsch Arztebl Int 107(16): 279-85 (2010)
2010 548	The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. [20490338] Dtsch Arztebl Int 107(17): 295-301 (2010)
2003 549	Inclusion of patients in clinical trial analysis: the intention-to-treat principle. [14558871] Med J Aust 179(8): 438-40 (2003)
2004 550	Biostatistics 203. Survival analysis. [15181518] Singapore Med J 45(6): 249-56 (2004)
2004 551	Biostatistics 302. Principal component and factor analysis. [15568116] Singapore Med J 45(12): 558-65, quiz 566 (2004)
2005 552	Biostatistics 303. Discriminant analysis. [15678285] Singapore Med J 46(2): 54-61; quiz 62 (2005)
2005 553	Biostatistics 306. Log-linear models: poisson regression. [16049606] Singapore Med J 46(8): 377-85; quiz 386 (2005)
2004 554	Systematic review of statistical methods used to analyze Seattle Angina Questionnaire scores. [15010742] Can J Cardiol 20(2): 187-93 (2004)
2007 555	Statistical errors in medical research--a chronic disease? [17299668] Swiss Med Wkly 137(3-4): 41-3 (2007)
2007 556	Statistical errors in medical research--a review of common pitfalls. [17299669] Swiss Med Wkly 137(3-4): 44-9 (2007)
2004 557	Statistical methods for linking health, exposure, and hazards. [15471740] Environ Health Perspect 112(14): 1440-5 (2004)
2004 558	Accounting for historical information in designing experiments: the Bayesian approach. [15536267] Ann Ist Super Sanita 40(2): 173-9 (2004)
2007 559	Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. [17387301] Cancer Control 14(2): 160-6 (2007)
2002 560	Confidence in statistical analysis. [12453920] Br J Anaesth 89(6): 807-10 (2002)
2003 561	Misuse of standard error of the mean (SEM) when reporting variability of a sample. A critical evaluation of four anaesthesia journals. [12644429] Br J Anaesth 90(4): 514-6 (2003)
2007 562	Using the Bland-Altman method to measure agreement with repeated measures. [17702826] Br J Anaesth 99(3): 309-11 (2007)
2010 563	Equivalence and noninferiority testing in anesthesiology research. [20808211] Anesthesiology 113(4): 779-81 (2010)
2010 564	Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. [20537177] BMC Med Res Methodol 10(-): 54 (2010)
2011 565	Questions asked and answered in pilot and feasibility randomized controlled trials. [21846349] BMC Med Res Methodol 11(-): 117 (2011)
2011 566	Simulation methods to estimate design power: an overview for applied research. [21689447] BMC Med Res Methodol 11(-): 94 (2011)
2011 567	The case study approach. [21707982] BMC Med Res Methodol 11(-): 100 (2011)
2002 568	Simpson's paradox and calculation of number needed to treat from meta-analysis. [11860604] BMC Med Res Methodol 2(-): 1 (2002)
2002 569	Pooling data for number needed to treat: no problems for apples. [11860605] BMC Med Res Methodol 2(): 2 (2002)
2002 570	Meta-analysis, Simpson's paradox, and the number needed to treat. [11860606] BMC Med Res Methodol 2(): 3 (2002)
2002 571	Markers for early detection of cancer: statistical guidelines for nested case-control studies. [11914137] BMC Med Res Methodol 2(-): 4 (2002)
2002 572	Do multiple outcome measures require p-value adjustment? [12069695] BMC Med Res Methodol 2(-): 8 (2002)
2002 573	Statistical issues in randomized trials of cancer screening. [12238954] BMC Med Res Methodol 2(-): 11 (2002)
2010 574	A systematic review of models to predict recruitment to multicentre clinical trials. [20604946] BMC Med Res Methodol 10(-): 63 (2010)
2010 575	What is a pilot or feasibility study? A review of current practice and editorial policy. [20637084] BMC Med Res Methodol 10(-): 67 (2010)
2011 576	Calculating unreported confidence intervals for paired data. [21569392] BMC Med Res Methodol 11(-): 66 (2011)
2011 577	Parametric methods outperformed non-parametric methods in comparisons of discrete numerical variables. [21489231] BMC Med Res Methodol 11(-): 44 (2011)
2011 578	Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance. [21510899] BMC Med Res Methodol 11(-): 55 (2011)
2008 579	Regression toward the mean--a detection method for unknown population mean based on Mee and Chua's algorithm. [18687143] BMC Med Res Methodol 8(-): 52 (2008)
2008 580	Advantages of the nested case-control design in diagnostic research. [18644127] BMC Med Res Methodol 8(-): 48 (2008)
2005 581	Systems validation: application to statistical programs. [15649319] BMC Med Res Methodol 5(1): 3 (2005)
2009 582	Evidence synthesis as the key to more coherent and efficient research. [19405972] BMC Med Res Methodol 9(-): 29 (2009)
2008 583	The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. [18366697] BMC Med Res Methodol 8(-): 12 (2008)
2008 584	Assessing the order of magnitude of outcomes in single-arm cohorts through systematic comparison with corresponding cohorts: an example from the AMOS study. [18366683] BMC Med Res Methodol 8(-): 11 (2008)
2008 585	The impact of consent on observational research: a comparison of outcomes from consenters and non consenters to an observational study. [18387187] BMC Med Res Methodol 8(-): 15 (2008)
2007 586	Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. [18199854] Mol Interv 7(6): 325-34 (2007)
2006 587	What are open-label extension studies for? [16583468] J Rheumatol 33(4): 642-3 (2006)
2004 588	Trials are short, disease long: measuring drug utility beyond clinical trials. [14760785] J Rheumatol 31(2): 205-6 (2004)
2004 589	Are individual patient trials (n-of-1 trials) in rheumatology worth the extra effort? [14705210] J Rheumatol 31(1): 8-11 (2004)
2008 590	Do Lego guns cause crime?: A light-hearted review of case-control, cohort, and RCT study designs. [19005135] Can Fam Physician 54(11): 1635-6 (2008)
2009 591	Recruiting issues in community-based studies: some advice from lessons learned. [19439712] Can Fam Physician 55(5): 557-8 (2009)
2010 592	Corporate influence over planning and presentation of clinical trials: beauty and the beast. [20014930] Expert Rev Cardiovasc Ther 8(1): 7-9 (2010)
2002 593	What makes a good case-control study? Design issues for complex traits such as endometriosis. [12042253] Hum Reprod 17(6): 1415-23 (2002)
2007 594	Insights into how to conduct a clinical trial in the UK. [17911130] J R Soc Med 100(10): 469-72 (2007)
2005 595	Understanding measures of treatment effect in clinical trials. [15613512] Arch Dis Child 90(1): 54-6 (2005)
2008 596	Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. [18489611] Br J Clin Pharmacol 66(2): 266-75 (2008)
2011 597	Significance testing as perverse probabilistic reasoning. [21356064] BMC Med 9(-): 20 (2011)
2009 598	What is stochastic resonance? Definitions, misconceptions, debates, and its relevance to biology. [19562010] PLoS Comput Biol 5(5): e1000348 (2009)
2002 599	A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments. [12016052] Bioinformatics 18(4): 546-54 (2002)
2010 600	Biomarker detection in the integration of multiple multi-class genomic studies. [19965884] Bioinformatics 26(3): 333-40 (2010)
2005 601	Classification using partial least squares with penalized logistic regression. [15531609] Bioinformatics 21(7): 1104-11 (2005)
2008 602	Implications of clinical trial design on sample size requirements. [18469326] Schizophr Bull 34(4): 664-9 (2008)
2002 603	The use of capture-recapture methods in public health. [12481204] Bull World Health Organ 80(11): 845 (2002)
2002 604	Using the two-source capture-recapture method to estimate the incidence of acute flaccid paralysis in Victoria, Australia. [12481205] Bull World Health Organ 80(11): 846-51 (2002)
2011 605	Reproducibility in research. [21555327] Dis Model Mech 4(3): 279-80 (2011)
2010 606	N-of-1 trials: a new future? [20632123] J Gen Intern Med 25(9): 891-2 (2010)
2009 607	Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. [19058232] Inflamm Bowel Dis 15(3): 422-8 (2009)
2011 608	Assessing the benefit: risk ratio of a drug--randomized and naturalistic evidence. [21842615] Dialogues Clin Neurosci 13(2): 183-90 (2011)
2011 609	Evaluation of psychiatric interventions in an observational study: issues in design and analysis. [21842616] Dialogues Clin Neurosci 13(2): 191-8 (2011)
2011 610	Effectiveness studies: advantages and disadvantages. [21842617] Dialogues Clin Neurosci 13(2): 199-207 (2011)
2011 611	A pragmatic view on pragmatic trials. [21842619] Dialogues Clin Neurosci 13(2): 217-24 (2011)
2011 612	Clinical trials in the era of personalized oncology. [22034206] CA Cancer J Clin 61(6): 365-81 (2011)
2010 613	The hazards of endpoints. [20826734] J Natl Cancer Inst 102(18): 1376-7 (2010)
2002 614	Screening trials are even more difficult than we thought they were. [11830599] J Natl Cancer Inst 94(3): 156-7 (2002)
2004 615	Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. [15240782] J Natl Cancer Inst 96(13): 990-7 (2004)
2004 616	Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. [15240771] J Natl Cancer Inst 96(13): 977-8 (2004)
2011 617	Reporting of factorial trials of complex interventions in community settings: a systematic review. [21771302] Trials 12(-): 179 (2011)
2011 618	Who is the research subject in cluster randomized trials in health research? [21791064] Trials 12(-): 183 (2011)
2011 619	The challenges and opportunities of conducting a clinical trial in a low resource setting: the case of the Cameroon mobile phone SMS (CAMPS) trial, an investigator initiated trial. [21658262] Trials 12(-): 145 (2011)
2011 620	Using a business model approach and marketing techniques for recruitment to clinical trials. [21396088] Trials 12(-): 74 (2011)
2011 621	Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. [21418571] Trials 12(-): 81 (2011)
2011 622	"Flogging dead horses": evaluating when have clinical trials achieved sufficiency and stability? A case study in cardiac rehabilitation. [21418648] Trials 12(-): 83 (2011)
2011 623	Standard requirements for GCP-compliant data management in multinational clinical trials. [21426576] Trials 12(-): 85 (2011)
2011 624	Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. [21612611] Trials 12(-): 134 (2011)
2011 625	Through the looking glass: understanding non-inferiority. [21539749] Trials 12(-): 106 (2011)
2011 626	Practices, patients and (im)perfect data--feasibility of a randomised controlled clinical drug trial in German general practices. [21457558] Trials 12(-): 91 (2011)
2011 627	Resources for authors of reports of randomized trials: harnessing the wisdom of authors, editors, and readers. [21504615] Trials 12(-): 98 (2011)
2011 628	Ethical issues posed by cluster randomized trials in health research. [21507237] Trials 12(-): 100 (2011)
2011 629	Investigator experiences with financial conflicts of interest in clinical trials. [21226951] Trials 12(-): 9 (2011)
2010 630	Reporting bias in medical research - a narrative review. [20388211] Trials 11(-): 37 (2010)
2010 631	A systematic review of techniques and interventions for improving adherence to inclusion and exclusion criteria during enrolment into randomised controlled trials. [20178571] Trials 11(-): 17 (2010)
2009 632	Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists. [19272166] Trials 10(-): 15 (2009)
2009 633	The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost. [19265515] Trials 10(-): 14 (2009)
2009 634	Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. [19413903] Trials 10(-): 29 (2009)
2008 635	Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'. [18423021] Trials 9(-): 20 (2008)
2009 636	Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). [19580665] Trials 10(-): 49 (2009)
2009 637	Compliance of clinical trial registries with the World Health Organization minimum data set: a survey. [19624821] Trials 10(-): 56 (2009)
2010 638	Selection bias and information bias in clinical research. [20407272] Nephron Clin Pract 115(2): c94-9 (2010)
2010 639	Measures of effect in epidemiological research. [20407271] Nephron Clin Pract 115(2): c91-3 (2010)
2010 640	Observational studies are complementary to randomized controlled trials. [19955822] Nephron Clin Pract 114(3): c173-7 (2010)
2011 641	Are you "tilting at windmills" or undertaking a valid clinical trial? [21786433] Yonsei Med J 52(5): 701-16 (2011)
2002 642	Summary for patients. Paying research subjects: a survey of current policies. [11874330] Ann Intern Med 136(5): I38 (2002)
2010 643	Aggregating and disaggregating patients in clinical trials and their subgroup analyses. [20621903] Ann Intern Med 153(1): 51-2 (2010)
2007 644	Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis. [17514615] J Nephrol 20(2): 119-29 (2007)
2009 645	Clinical research in pediatric nephrology: challenges, and strategies to address them. [19967646] J Nephrol 22(6): 685-93 (2009)
2008 646	Ordinal logistic regression models: application in quality of life studies. [18797732] Cad Saude Publica 24 Suppl 4(-): s581-91 (2008)
2009 647	In silico preclinical trials: methodology and engineering guide to closed-loop control in type 1 diabetes mellitus. [20144358] J Diabetes Sci Technol 3(2): 269-82 (2009)
2009 648	Methods for equivalence and noninferiority testing. [19147090] Biol Blood Marrow Transplant 15(1 Suppl): 120-7 (2009)
2007 649	A systematic review of the quality of publications reporting coronary artery bypass grafting trials. [17897515] Can J Surg 50(4): 266-77 (2007)
2004 650	Mechanisms of regression. [15931340] Clin Med Res 2(2): 85-8 (2004)
2005 651	New methodology in biomedical science: methodological errors in classical science. [15687745] Medicina (Kaunas) 41(1): 7-16 (2005)
2011 652	The evolution of phase I trials in cancer medicine: a critical review of the last decade. [22059910] Chin J Cancer 30(12): 815-20 (2011)
2010 653	The role of the statistical editor. [20658048] Rev Bras Psiquiatr 32(2): 102 (2010)
2004 654	Receiver operating characteristic (ROC) curve: practical review for radiologists. [15064554] Korean J Radiol 5(1): 11-8 (2004)
2002 655	Randomised controlled trials in primary care: scope and application. [12236280] Br J Gen Pract 52(482): 746-51 (2002)
2002 656	The power of statistics. [12236290] Br J Gen Pract 52(482): 766-7 (2002)
2007 657	The case of 'protective fever and chest signs': towards a better understanding of general practice databases. [17727742] Br J Gen Pract 57(540): 523-5 (2007)
2005 658	N-of-1 trials: an opportunity to tailor treatment in individual patients. [15808030] Br J Gen Pract 55(512): 171-2 (2005)
2005 659	N-of-1 trials of quinine efficacy in skeletal muscle cramps of the leg. [15808032] Br J Gen Pract 55(512): 181-5 (2005)
2009 660	Methods for analysing cardiovascular studies with repeated measures. [19949712] Neth Heart J 17(11): 429-33 (2009)
2011 661	Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology. [21305479] Cardiol J 18(1): 3-7 (2011)
2002 662	Meta-analyses involving cross-over trials: methodological issues. [11914310] Int J Epidemiol 31(1): 140-9 (2002)
2002 663	Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. [11914304] Int J Epidemiol 31(1): 107-11 (2002)
2010 664	Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. [20439481] Int J Epidemiol 39(5): 1345-59 (2010)
2010 665	DataSHIELD: resolving a conflict in contemporary bioscience--performing a pooled analysis of individual-level data without sharing the data. [20630989] Int J Epidemiol 39(5): 1372-82 (2010)
2010 666	Commentary: like it and lump it? Meta-analysis using individual participant data. [20660642] Int J Epidemiol 39(5): 1359-61 (2010)
2010 667	Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies. [20813861] Int J Epidemiol 39(5): 1383-93 (2010)
2008 668	Critical reading of the statistical data in scientific studies. [19378522] Rev Bras Anestesiol 58(3): 260-6 (2008)
2012 669	Standards for reporting randomized controlled trials in medical informatics: a systematic review of CONSORT adherence in RCTs on clinical decision support. [21803926] J Am Med Inform Assoc 19(1): 13-21 (2012)
2010 670	Use of statistical analysis in the biomedical informatics literature. [20064794] J Am Med Inform Assoc 17(1): 3-5 (2010)
2010 671	How to develop patient-centered research: some perspectives based on surveys among people with rheumatic diseases in Scandinavia. [20110341] Phys Ther 90(3): 450-60 (2010)
2011 672	Researchers' experience with project management in health and medical research: results from a post-project review. [21635721] BMC Public Health 11(-): 424 (2011)
2011 673	A systematic review of the effect of retention methods in population-based cohort studies. [21504610] BMC Public Health 11(-): 249 (2011)
2011 674	Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. [22104038] BMC Public Health 11(-): 880 (2011)
2008 675	Methodologies used to estimate tobacco-attributable mortality: a review. [18211696] BMC Public Health 8(-): 22 (2008)
2010 676	Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. [20172362] Semin Oncol 37(1): 31-8 (2010)
2011 677	Why hypotheses informed by observation are often wrong: results of randomized controlled trials challenge chronic disease management strategies based on epidemiological evidence. [21434699] J Manag Care Pharm 17(3): 224-31 (2011)
2009 678	What should be done about bias and misconduct in clinical trials? [19236130] J Manag Care Pharm 15(2): 154-60 (2009)
2009 679	When is a case-control study not a case-control study? [19247538] J Rehabil Med 41(4): 209-16 (2009)
2005 680	Clinimetrics in rehabilitation medicine: current issues in developing and applying measurement instruments 1. [16024474] J Rehabil Med 37(4): 193-201 (2005)
2008 681	Critical reading of the statistical data in scientific studies. [19082330] Rev Bras Cir Cardiovasc 23(3): 396-9 (2008)
2009 682	The use of electronic data capture tools in clinical trials: Web-survey of 259 Canadian trials. [19275984] J Med Internet Res 11(1): e8 (2009)
2009 683	Validation of novel imaging methodologies for use as cancer clinical trial end-points. [19091547] Eur J Cancer 45(2): 290-9 (2009)
2009 684	Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. [19091546] Eur J Cancer 45(5): 741-6 (2009)
2007 685	Practical Bayesian adaptive randomisation in clinical trials. [17306975] Eur J Cancer 43(5): 859-66 (2007)
2011 686	Sequential methods for random-effects meta-analysis. [21472757] Stat Med 30(9): 903-21 (2011)
2010 687	One-stage parametric meta-analysis of time-to-event outcomes. [20963770] Stat Med 29(29): 3030-45 (2010)
2010 688	Sequential generalized likelihood ratio tests for vaccine safety evaluation. [20799244] Stat Med 29(26): 2698-708 (2010)
2010 689	Real longitudinal data analysis for real people: building a good enough mixed model. [20013937] Stat Med 29(4): 504-20 (2010)
2009 690	Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. [19222086] Stat Med 28(7): 1067-92 (2009)
2009 691	A re-evaluation of the 'quantile approximation method' for random effects meta-analysis. [19016302] Stat Med 28(2): 338-48 (2009)
2009 692	Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. [19222087] Stat Med 28(8): 1218-37 (2009)
2009 693	Choosing an optimal method to combine P-values. [19266501] Stat Med 28(11): 1537-53 (2009)
2009 694	Synthesis analysis of regression models with a continuous outcome. [19326397] Stat Med 28(11): 1620-35 (2009)
2011 695	Part 2: implementing clinical trials: a review of the attributes of exemplary clinical trial sites. [21532813] J Oncol Pract 7(1): 61-4 (2011)
2011 696	Clinical investigator responsibilities. [21731522] J Oncol Pract 7(2): 124-8 (2011)
2009 697	Correct use of repeated measures analysis of variance. [19262072] Korean J Lab Med 29(1): 1-9 (2009)
2007 698	Approximating the variance of the conditional probability of the state of a hidden Markov model. [17672820] Stat Appl Genet Mol Biol 6(-): Article 18 (2007)
2008 699	Issues in outcomes research: an overview of randomization techniques for clinical trials. [18345348] J Athl Train 43(2): 215-21 (2008)
2010 700	Adaptive design clinical trials: Methodology, challenges and prospect. [20927243] Indian J Pharmacol 42(4): 201-7 (2010)
2002 701	Some general points in estimating heterogeneity variance with the DerSimonian-Laird estimator. [12933591] Biostatistics 3(4): 445-57 (2002)
2010 702	Bayesian inference for generalized linear mixed models. [19966070] Biostatistics 11(3): 397-412 (2010)
2009 703	A unification of models for meta-analysis of diagnostic accuracy studies. [19039031] Biostatistics 10(1): 201-3 (2009)
2008 704	An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown. [17626226] Biostatistics 9(1): 172-86 (2008)
2011 705	Adaptive designs in clinical trials. [21584178] Perspect Clin Res 2(1): 23-7 (2011)
2011 706	Intention-to-treat concept: A review. [21897887] Perspect Clin Res 2(3): 109-12 (2011)
2011 707	A review for clinical outcomes research: hypothesis generation, data strategy, and hypothesis-driven statistical analysis. [21359904] Surg Endosc 25(7): 2254-60 (2011)
2008 708	A clinician's guide to statistical methods in urologic oncology. [18452824] Urol Oncol 26(3): 299 (2008)
2011 709	Methodological quality of test accuracy studies included in systematic reviews in obstetrics and gynaecology: sources of bias. [21426545] BMC Womens Health 11(-): 7 (2011)
2011 710	The quality of reporting of primary test accuracy studies in obstetrics and gynaecology: application of the STARD criteria. [21429185] BMC Womens Health 11(-): 8 (2011)
2011 711	Multiple treatment comparison meta-analyses: a step forward into complexity. [21750628] Clin Epidemiol 3(-): 193-202 (2011)
2008 712	Analysis of variance: is there a difference in means and what does it mean? [17936790] J Surg Res 144(1): 158-70 (2008)
2010 713	Missing data analysis using multiple imputation: getting to the heart of the matter. [20123676] Circ Cardiovasc Qual Outcomes 3(1): 98-105 (2010)
2002 714	Regulatory issues for clinical trials in humans. [12119857] Epidemiol Rev 24(1): 59-66 (2002)
2010 715	Summarizing historical information on controls in clinical trials. [20156954] Clin Trials 7(1): 5-18 (2010)
2009 716	Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. [19528130] Clin Trials 6(3): 205-16 (2009)
2005 717	Systematic evaluation and comparison of statistical tests for publication bias. [16276033] J Epidemiol 15(6): 235-43 (2005)
2010 718	An introduction to epidemiologic and statistical methods useful in environmental epidemiology. [20431236] J Epidemiol 20(3): 177-84 (2010)
2006 719	How to randomize. [17022927] J Soc Integr Oncol 4(4): 194-8 (2006)
2010 720	A guide to organizing a multicenter clinical trial. [20375760] Plast Reconstr Surg 126(2): 515-23 (2010)
2008 721	Adjusted estimates for time-to-event endpoints. [18791867] Lifetime Data Anal 14(4): 484-95 (2008)
2008 722	Inference for outcome probabilities in multi-state models. [18791824] Lifetime Data Anal 14(4): 405-31 (2008)
2011 723	Review of the methods of determination of directed connectivity from multichannel data. [21298355] Med Biol Eng Comput 49(5): 521-9 (2011)
2010 724	Modelling the cumulative risk of a false-positive screening test. [20356857] Stat Methods Med Res 19(5): 429-49 (2010)
2009 725	Multi-state models for the analysis of time-to-event data. [18562394] Stat Methods Med Res 18(2): 195-222 (2009)
2010 726	A global sensitivity test for evaluating statistical hypotheses with nonidentifiable models. [19645705] Biometrics 66(2): 558-66 (2010)
2011 727	The use and abuse of multiple outcomes in randomized controlled depression trials. [21185405] Contemp Clin Trials 32(2): 299-304 (2011)
2010 728	Classical and modern measurement theories, patient reports, and clinical outcomes. [20129315] Contemp Clin Trials 31(1): 1-3 (2010)
2009 729	Role of animal studies in the design of clinical trials. [19478492] Front Neurol Neurosci 25(-): 10-33 (2009)
2010 730	Censoring in clinical trials: review of survival analysis techniques. [20922095] Indian J Community Med 35(2): 217-21 (2010)
2008 731	Clinical research methodology I: introduction to randomized trials. [18222393] J Am Coll Surg 206(2): 361-9 (2008)
2003 732	How to ... do a randomized controlled trial. [14634173] J Orthod 30(4): 337-41 (2003)
2010 733	CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. [21350618] J Pharmacol Pharmacother 1(2): 100-7 (2010)
2011 734	Moving beyond traditional null hypothesis testing: evaluating expectations directly. [21713172] Front Psychol 2(-): 24 (2011)
2009 735	Classification and error estimation for discrete data. [20436873] Curr Genomics 10(7): 446-62 (2009)
2010 736	Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. [20588256] Mol Ther 18(9): 1724-30 (2010)
2011 737	Laboratory and software applications for clinical trials: the global laboratory environment. [22074278] Bioanalysis 3(21): 2381-4 (2011)
2007 738	Understanding linear and logistic regression analyses. [17391582] CJEM 9(2): 111-3 (2007)
2008 739	Incorporation bias in studies of diagnostic tests: how to avoid being biased about bias. [18371254] CJEM 10(2): 174-5 (2008)
2010 740	Developing and Testing a Tool for the Classification of Study Designs in Systematic Reviews of Interventions and Exposures [21433333] (): (2010)
2010 741	The noninferiority trial: don't don't do it. [21087412] Am J Transplant 10(12): 2571-3 (2010)
2010 742	The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. [21119659] Br J Cancer 103(12): 1801-7 (2010)
2010 743	Categorical data analysis in experimental biology. [20826130] Dev Biol 348(1): 3-11 (2010)
2010 744	Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. [20863658] J Clin Epidemiol 63(12): 1312-23 (2010)
2011 745	Demystify statistical significance--time to move on from the p value to bayesian analysis. [21131578] J Natl Cancer Inst 103(1): 2-3 (2011)
2010 746	NCI's clinical trial system: efficiencies grow, debate goes on. [21088280] J Natl Cancer Inst 102(23): 1750-1, 1755 (2010)
2010 747	Biomarker-adaptive clinical trial designs. [21142910] Pharmacogenomics 11(12): 1679-82 (2010)
2010 748	Observational studies: cohort and case-control studies. [20697313] Plast Reconstr Surg 126(6): 2234-42 (2010)
2010 749	Handling missing data in randomized experiments with noncompliance. [20379779] Prev Sci 11(4): 384-96 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Statistics and trial design.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Statistics and trial design.php on line 92